Fact-Check: Verdicts on the Original Draft

The user's original draft (drafts/2026-04/libido.md) makes a series of claims about hormones, blood-flow enhancers, direct libido drugs, dampeners, and the refractory period. Each is verdicted below against the eight research deep dives. Tags: true the claim matches the published evidence; kind-of-true directionally right but with caveats or oversimplification; false contradicted by the evidence; understated the claim is too cautious relative to what the literature actually shows; not-evaluable insufficient evidence to verdict cleanly.

Framing — Two Axes of Libido

kind-of-true "Two axes" of libido: a masculine T-driven axis (always somewhat on, genital-localized, sharp post-orgasm drop, long refractory) versus a feminine E/P-driven axis (often off, slower ignition, body-wide sensitivity, short refractory, gradual post-orgasm decline).

The phenomenological population-level differences are real (Baumeister 2001 on spontaneous-cognition frequency; Chivers 2010 on arousal concordance; Levin 2009 on refractory-time differences), but the hormonal axis framing is a folk synthesis of Basson's responsive-desire model and lay sex-difference literature, not an indexed sexology construct. The "sharp post-orgasm T drop" specifically is wrong — what's sharp post-orgasm is prolactin elevation and dopamine drop, not testosterone. → hormones-foundations

Sex Hormones

kind-of-true "Testosterone has the strongest effect on libido."

True for postmenopausal cis women on background estrogen as a pharmacological intervention (Islam 2019: +0.85 satisfying events/month, SMD 0.36 for desire). False for endogenous physiology in premenopausal cis women — Wåhlin-Jacobsen 2017 found total T and DHEA-S not associated with HSDD; Roney & Simmons 2013 found that within-cycle daily desire is positively predicted by estradiol and negatively by progesterone, with T dropping out when E2 is controlled. Defreyne ENIGI also reports no within-person correlation between absolute serum T and SDI in either trans cohort. → hormones-foundations

kind-of-true "Transfeminine people often experience a HUGE drop in libido after lowering testosterone." "Transmasculine people often experience a HUGE surge upon raising testosterone."

Both are directionally correct at the population level. But "huge" is honest only for spontaneous T-driven urges and for the most thoroughly suppressing regimens (CPA, GnRH agonists, post-orchiectomy). 22% of trans women develop full HSDD versus 5% of trans men (Wierckx 2014). For trans men, by 36 months total/dyadic SDI scores have regressed back to baseline; only solitary desire stays elevated (Defreyne 2020). The within-person dose-response is much weaker than the population direction implies. → trans-specific-libido

true "Some women supplement testosterone to upper female range for higher libido without masculinization."

Endorsed by the Davis 2019 Global Consensus and 2021 ISSWSH CPG: target premenopausal physiological range (≈27-58 ng/dL total T), typically one-tenth of the male transdermal dose, or 5-10 mg/day AndroFeme 1% cream where available (Australia). The effect size is modest (≈1 extra satisfying event/month above placebo). "Without masculinization" is honest only at carefully titrated transdermal physiological-range dosing; pellet, IM and oral routes routinely overshoot, and meta-analyses still show acne and hirsutism increases. No FDA-approved T product for women in the US. → trans-specific-libido

kind-of-true "Estrogen has a relatively weaker effect on libido than testosterone." "Some transfem people regain a more feminine-style libido after long-term feminine hormones."

Half-right. Postmenopausal-HT clinical-trial endpoints show no-to-small libido effect from estrogen alone (2023 systematic review). But within-cycle physiology (Roney & Simmons; Cappelletti & Wallen) puts E2 in the lead role. The transfem rebound — Defreyne ENIGI shows total/dyadic SDI exceed baseline at 36 months while solitary returns to baseline — is real at the population level. The "feminine-style" qualitative restructuring is community lore that the longitudinal SDI data cannot directly validate. → hormones-foundations · → trans-specific-libido

not-evaluable "People do report higher libido on Progesterone if their libido was low on Estrogen."

No high-quality RCT supports this. Saadat 2002, Wren 2003, the Saraf 2023 transfem cohort, Roney & Simmons 2013, and the broader Cappelletti-Wallen synthesis all point to neutral-or-suppressive progesterone effects on desire. The "raises libido in some" anecdote could plausibly reflect allopregnanolone-mediated anxiolysis or sleep / mood improvement rather than primary desire effect. → progestins-and-progesterone · → hormones-foundations

kind-of-true "Synthetic progestins typically lower libido. MPA is one example."

MPA is correct as a canonical pregnane progestin. "Typically lower libido" overstates the population-level signal — Pastor 2013 (n=13,673) found 85% of COC users had unchanged or increased libido, 15% decreased. The effect is class- and context-dependent: profound suppression at high anti-androgen / forensic doses; modest signal in DMPA / implant / ring users (37% vs 18% on copper IUD in Boozalis 2016); near-null signal for LNG-IUS. → progestins-and-progesterone

kind-of-true Question: "How exactly do progestins lower libido — by lowering testosterone?"

Lowering T is the dominant mechanism at high anti-androgen doses (CPA, MPA in forensic dosing) and a major mechanism in ovulation-suppressing systemic contraception. But there are at least four other pathways: (1) SHBG elevation by ethinyl estradiol, which lowers free T disproportionately; (2) suppression of ovarian estradiol (DMPA, implant, ring); (3) direct AR antagonism (CPA, dienogest, drospirenone, chlormadinone); (4) direct CNS effects via PR-expressing hypothalamic neurons and via allopregnanolone-driven mood/affect changes. The Michael & Zumpe 1993 primate experiment is the cleanest dissociation: MPA suppressed sexual behaviour even when systemic T was held in normal range. → progestins-and-progesterone · → libido-dampeners

Blood Flow Enhancers (PDE5)

true "Sildenafil/Viagra is a blood-flow enhancer; it makes erections easier and does not generally affect libido directly."

Consistent with the FDA label and StatPearls mechanism. Mild caveat: there is preclinical and limited human evidence of central effects (dopaminergic / serotonergic in MPOA and NAcc, modest fMRI signals) and a real reduction in postejaculatory refractory time. The dominant clinical action is peripheral vasodilation. → pde5-inhibitors

kind-of-true "Tadalafil is basically a longer-lasting version of Sildenafil." "Tadalafil half-life 17.5 h, sildenafil half-life 4 h."

The half-life numbers exactly match FDA labels. "Longer-lasting version" is a useful first approximation but understates real differences: tadalafil is a structurally different molecule, much more PDE6-selective (550× vs sildenafil's 16×, hence less blue-tint vision), has a separate FDA-approved BPH indication (5 mg daily, since 2011), and is food-effect-independent. → pde5-inhibitors

kind-of-true "Contraindicated with some few medical conditions and other medications. Generally has few side effects."

"Some few" understates the seriousness. Nitrates and riociguat are absolute contraindications because of potentially fatal hypotension. Doxazosin / terazosin co-administration requires care. Severe hepatic impairment and several PAH-specific conditions narrow eligibility. Common side effects (headache 10-16%, flushing 10%, dyspepsia, nasal congestion, back pain with tadalafil, transient visual disturbances with sildenafil) are usually self-limited; rare serious complications (NAION, sudden hearing loss, priapism) are real. → pde5-inhibitors

understated "Weak evidence it might be correlated with reduced all-cause mortality for older people."

"Weak" no longer fits the literature. Andersson JACC 2021 (16,548 men with prior MI/revascularization, alprostadil active comparator) showed HR 0.88 with a clear dose-response. Anderson 2017 type-2-diabetes cohort, Kloner Clin Cardiol 2024 (HR 0.56 for tadalafil, HR 0.40 in top exposure quartile), Jehle AJM 2024 (TriNetX, n>500k), Mostafa 2024 systematic review and meta-analysis, and Xiao 2025 Mendelian-randomization analysis all point in the same direction. Healthy-user bias is real and partial; "consistent observational evidence with residual confounding, no randomized confirmation" is a more honest summary. → pde5-inhibitors

Direct Libido Enhancers (Bremelanotide / Melanotan II)

kind-of-true "Bremelanotide / PT-141 is FDA-approved as a libido-enhancing drug, used to treat low sexual desire in women."

Vyleesi was FDA-approved 21 June 2019 — but for the narrow indication of premenopausal women with acquired, generalized HSDD. The label has explicit "Limitations of Use": not approved for postmenopausal women, not for men, not for "enhancement of sexual performance." Calling it "FDA-approved for libido enhancement" is broader than the label allows. Also note that flibanserin (Addyi) was approved four years earlier (August 2015) and was the actually-first FDA-approved HSDD drug; the draft inverted the chronology. → melanocortin-pt141 · → missed-topics

true "Typically administered by injection. Half-life 2-4 hours."

Approved formulation is 1.75 mg subcutaneous autoinjector (abdomen or thigh), at least 45 minutes before activity, max one dose per 24 h, max 8 doses per month. Mean terminal half-life 2.7 h (range 1.9-4.0 h). Earlier intranasal formulations were dropped because of variable kinetics and blood-pressure problems. → melanocortin-pt141

true "Effects can be useful or modest depending on the person."

RECONNECT phase-3 trials show ≈58% bremelanotide responders versus ≈36% placebo responders on FSFI-D (drug-vs-placebo difference ≈22 percentage points). The placebo response is enormous, which is the standard pattern in HSDD trials. The marginal drug effect is real but small in absolute terms; some women experience clear benefit and others little or none. → melanocortin-pt141

kind-of-true "Has more potential side effects than PDE5i."

Directionally correct. Bremelanotide: nausea ≈40%, flushing ≈20%, headache ≈11%, injection-site reactions ≈13%, focal hyperpigmentation, transient hypertension (≈+6 mmHg systolic, peaks at ~2 h), contraindicated in uncontrolled hypertension or known CV disease. PDE5i: headache ≈15%, flushing ≈10%, dyspepsia, vision changes (sildenafil), back pain (tadalafil), absolute contraindication with nitrates, rare NAION / hearing loss / priapism. The shape of the side-effect profiles is qualitatively different; bremelanotide's load is heavier on average. → melanocortin-pt141

true "Hyperpigmentation is a rare (~1 in 100) side effect, for interesting reasons."

FDA label: focal hyperpigmentation in ≈1% at the labeled max of 8 doses/month, rising to ≈38% at 16 consecutive daily doses. Mechanism: bremelanotide is a structural cyclic-lactam α-MSH analog and retains residual MC1R agonism, which drives cAMP-mediated tyrosinase transcription and eumelanin synthesis. Affected sites in published reports include face, gingiva, areolae, breasts. → melanocortin-pt141

true "Melanotan II is a peptide used to increase melanin production, was found to raise libido, and was used as inspiration for PT-141."

Historically correct. The Wessells 1998 J Urol study (n=10) and Wessells 2000 IJIR study established the libido / erectile signal in MT-II at the University of Arizona; Palatin's PT-141 program was a structure-activity-driven attempt to keep that signal while reducing MC1R activity by changing the C-terminal amide to a free carboxylic acid. → melanocortin-pt141

true "If you want to use either, use PT-141 (not MT-II)." (with framing tightening)

Direction is correct. The honest version is stronger: bremelanotide / Vyleesi is the only defensible choice for any libido use case because it has FDA approval, validated PK, manufacturer quality controls, and a documented adverse-event profile. Melanotan II is unapproved gray-market peptide of unknown purity with case reports of melanoma diagnosed during use (Cardones & Grichnik 2014), rhabdomyolysis with AKI (Nelson 2012), priapism, and renal infarction. The recommendation should be "do not use MT-II" rather than "use the better of the two." → melanocortin-pt141

Direct Libido Dampeners

kind-of-true "Synthetic progestins help" [as dampeners].

As above — the mechanism is multi-pathway. The dominant route at high anti-androgen doses (CPA, MPA) is HPG-axis suppression and resulting low T. At contraceptive doses the picture is more equivocal (Pastor 2013) and likely involves SHBG elevation, ovarian E2 suppression (DMPA / implant / ring particularly), direct AR antagonism (CPA / drospirenone / dienogest / chlormadinone), and some CNS effects. The category "synthetic progestins" is too coarse — CPA and high-dose MPA earn a "direct dampener" label cleanly; LNG-IUS arguably does not at all. → progestins-and-progesterone · → libido-dampeners

understated Other major dampener classes the draft did not enumerate.

SSRIs / SNRIs (Montejo 2001: 57-71% prevalence depending on agent; bupropion and mirtazapine notably lower; PSSD as a regulator-recognized persistent post-discontinuation syndrome). Antiandrogens (spironolactone / CPA / bicalutamide / GnRH agonists / abiraterone). 5α-reductase inhibitors (finasteride / dutasteride; PFS as the analogue to PSSD). Opioid-induced androgen deficiency (OPIAD). Alcohol use disorder. Beta blockers (especially propranolol / atenolol; nebivolol notably preserves function). Antipsychotics that raise prolactin (risperidone, paliperidone, haloperidol; aripiprazole as the partial-D2-agonist exception). Glucocorticoid therapy. Hyperprolactinemia, hypothyroidism, hypogonadism, depression itself, sleep deprivation. → libido-dampeners

Refractory Period

true "Little research on how to affect refractory period directly."

If anything understated. There is essentially no controlled clinical research with refractory-period reduction as a primary endpoint. Levin 2009 explicitly notes that even the canonical Masters & Johnson description of an obligatory refractory period had no underlying experimental data. → refractory-period-prolactin

true "There are separable neural circuits for orgasm and ejaculation."

Strong anatomical and clinical evidence. Truitt & Coolen 2002 (Science) identified the lumbar spinothalamic (LSt) NK1R+ neurons in L3-L4 as a "spinal ejaculation generator." Clinical evidence: anejaculatory orgasm (post-prostatectomy, alpha-blocker, SCI), retrograde ejaculation, orgasmic anhedonia. Orgasm is supraspinal (NAcc, ventral pallidum, ACC, insula, MPOA); ejaculation is spinal-LSt + autonomic. → refractory-period-prolactin

kind-of-true "Ejaculation and refractory period are affected by testosterone-driven maturation."

True developmentally — pubertal androgens are required to assemble the LSt circuit and MPOA AR density. False hormonally-dynamically — circulating testosterone in adult men does not predict refractory length, and high physiological T does not shorten PERT. → refractory-period-prolactin

kind-of-true "Might be possible to manipulate the circuits separately to alter refractory period."

In principle yes — PDE5 inhibitors already do this in a limited sense by restoring peripheral erection without resolving central refractoriness. PT-141 / cabergoline / naltrexone / behavioural decoupling are theoretical levers but lack adequate trials. → refractory-period-prolactin

kind-of-true "Some research on prolactin being a factor, but unclear and contested."

Understates how much the consensus has shifted. Levin 2009 and Turley & Rowland 2013 already pushed back on the prolactin-causation hypothesis. Valente, Marques and Lima (Communications Biology 2021) used a peripherally-restricted dopamine antagonist (domperidone) to elevate prolactin without confounding central D2 effects in mice and showed no change in refractory period. The post-orgasmic prolactin spike is real but is probably a downstream marker, not a causal upstream regulator. "Probably wrong" is closer than "unclear and contested." → refractory-period-prolactin

kind-of-true Quoted Krüger 2003 cabergoline finding and refractory-period claim.

The verbatim quote ("Administration of cabergoline decreased prolactin levels and significantly enhanced all parameters of sexual drive (P<0.05), function (P<0.01) and positive perception of the refractory period (P<0.01)") is real but the citation in the draft is wrong: it is Krüger TH et al., Journal of Endocrinology 2003; 179(3):357-365, PMID 14656205, not "Krüger 2003 Lancet." The design was single-blind balanced crossover with n=10, not double-blind. The outcome was self-reported "positive perception" of refractory period, not measured shortening. The cabergoline effect almost certainly reflects central D2 agonism rather than prolactin reduction (Lima 2021 shows). The result has not been independently replicated at scale. → refractory-period-prolactin

true "Cabergoline half-life is ~65 hours."

FDA Dostinex label and Del Dotto 2003 PK review give 63-69 h in healthy subjects, longer (79-115 h) in patients with pituitary tumours. → refractory-period-prolactin

kind-of-true "Long-term high doses can lead to heart valve failure."

True at Parkinson's-scale doses (≥3 mg/day cumulative; the signal that effectively ended cabergoline's use as a Parkinson's drug). At prolactinoma-scale doses (0.25-2 mg/week), the Stiles 2018 meta-analysis found increased odds of mild tricuspid regurgitation (OR 3.74) but no increase in clinically significant valvular dysfunction, and the 2021 Drake CATCH cohort using hard endpoints found no excess valve repair/replacement. Endocrine guidance now recommends baseline echo only for cumulative >2 mg/week or treatment >5 years. The framing should distinguish dose ranges. → refractory-period-prolactin

kind-of-true "Mostly only used to treat prolactinomas and Parkinson's disease."

Prolactinoma / hyperprolactinemia is the dominant current indication. Parkinson's disease is largely historical — cabergoline has been displaced by safer dopamine agonists (pramipexole, ropinirole, rotigotine). Off-label uses include postpartum lactation suppression in some markets, restless legs syndrome rarely, the small male sexual-medicine literature, and retrospective use in compulsive sexual behaviour. → refractory-period-prolactin

What the draft missed entirely

false Implicit chronology: bremelanotide is the prototype FDA-approved direct libido drug.

Flibanserin (Addyi) was approved 18 August 2015 for premenopausal HSDD — four years before bremelanotide (June 2019). Different pharmacology: chronic daily oral 5-HT1A full agonist / 5-HT2A antagonist / weak D4 partial agonist, not on-demand subcutaneous melanocortin agonist. The Jaspers 2016 JAMA Internal Medicine meta-analysis pooled 8 trials and found ≈0.49 additional satisfying sexual events per month with significant adverse-event burden (4× dizziness, 2× somnolence/fatigue/nausea). Approval was contentious (Even The Score advocacy campaign; FDA had rejected twice before). Alcohol contraindication softened in 2019. → missed-topics

understated The placebo-response problem in HSDD trials.

Placebo responder rates run 35-45% in HSDD trials — comparable to the active-arm rate for flibanserin and within striking distance of bremelanotide. Trial enrolment is itself a behavioural and relational intervention (self-identified distress, attention from clinicians, mandatory tracking and partner conversations, expectancy effects). Any drug whose active-minus-placebo delta is ≈1 extra event per month is operating in the noise floor. → missed-topics

understated The dopamine system, bupropion, the wanting-vs-liking framework.

Apomorphine sublingual (EU 2001-2006) was the closest-to-approved central dopaminergic on-demand ED drug. Pramipexole and ropinirole induce hypersexuality in ≈2-8% of Parkinson's patients via D3-skewed mesolimbic agonism — the cleanest naturalistic human evidence that dopamine elevation drives sexual motivation. Bupropion (NDRI) is the obvious first-line answer to "my SSRI killed my libido": Clayton 2004 RCT, Safarinejad 2010 male SRI-induced dysfunction trial, multiple women-specific systematic reviews. Berridge & Robinson's wanting-vs-liking dissociation is the conceptual frame that explains why "more dopamine" is not a clean win. → missed-topics

understated Kisspeptin as the credible next-gen candidate class.

The Comninos / Imperial College programme (J Clin Invest 2017, PNAS 2018, JAMA Network Open 2022 in men with HSDD, JAMA Network Open 2022 in women with HSDD) shows IV kisspeptin enhances limbic and paralimbic activity to sexual cues, reduces sexual aversion, and produces measurable behavioural and physiological signals. Not yet a drug — IV only, oral analogues in early development — but the most exciting forward-looking pharmacology in the field. → missed-topics

understated Basson's responsive-desire model, DSM-5 FSIAD, and the Coolidge effect.

Basson 2000 showed many women's desire is responsive (emerges after engagement) rather than spontaneous (precedes it). DSM-5 collapsed HSDD and FSAD into FSIAD in 2013 to reflect that. Coolidge effect (sexual interest renews on partner novelty; mediated by mesolimbic dopamine) plus relationship-duration desire decline (Klusmann 2002) mean that for many people the dominant variable is relational context, not neurochemistry. Drugs that try to manufacture spontaneous urge will produce small effects almost by construction. → missed-topics